Other adverse events (allergy, irritation/burning of nasal, oral or oropharyngeal mucosa, long-term staining of mucous membranes or teeth, accidental ingestion) · Patients with suspected or confirmed COVID-19 infection
The review found no eligible studies for this question.
1 finding from 1 review
Adverse events ‐ not reported · participants with chronic prostatitis/chronic pelvic pain syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Other adverse events (allergy, irritation/burning of nasal, oral or oropharyngeal mucosa, long-term staining of mucous membranes or teeth, accidental ingestion) · Healthcare workers (HCWs) treating patients with suspected or confirmed COVID-19 infection
The review found no eligible studies for this question.
1 finding from 1 review
Other adverse events (allergy, irritation/burning of nasal, oral or oropharyngeal mucosa, long-term staining of mucous membranes or teeth, accidental ingestion) · Patients without suspected or confirmed COVID-19 infection undergoing aerosol-generating procedures (AGPs), and the healthcare workers…
The review found no eligible studies for this question.
1 finding from 1 review
Adverse events:infection · adults with chronic pain
Active stimulation + other intervention may leads to higher adverse events:infection compared with other intervention alone (low certainty).
1 finding from 1 review
Adverse events: infection · adults with chronic pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events ‐ matting ( · people with telangiectasias and reticular veins
Sclerotherapy plus compression showed no clear difference in adverse events ‐ matting ( compared with sclerotherapy alone (low certainty).
1 finding from 1 review
Adverse events · Adults receiving chemotherapy alone for colorectal cancer
1 finding from 1 review
Adverse events at 3 to 12 months' · eyes with acute endophthalmitis following an intraocular procedure (e.g. surgery, intravitreous injection)
Combined steroid and antibiotic therapy showed no clear difference in adverse events at 3 to 12 months' compared with antibiotics alone (low certainty).
1 finding from 1 review
Adverse events ‐ hyperpigmentation ( · people with telangiectasias and reticular veins
Sclerotherapy plus compression showed no clear difference in adverse events ‐ hyperpigmentation ( compared with sclerotherapy alone (moderate certainty).
1 finding from 1 review
Adverse events (maternal or neonatal) · women undergoing caesarean section
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Treatment adverse events: UTI/pyelonephritis · kidney transplant recipients: first rejection episode
Rituximab (B cell) + steroid probably leads to higher treatment adverse events: UTI/pyelonephritis compared with steroid alone (moderate certainty).
1 finding from 1 review
Proportion of infants with serious adverse events ( · HIV‐positive pregnant women co‐infected with hepatitis B virus
It is very uncertain whether tenofovir‐based antiviral combination regimens changes proportion of infants with serious adverse events ( compared with placebo or tenofovir alone or non‐tenofovir‐based antiviral regimens (very low certainty).
1 finding from 1 review
Proportion of mothers with serious adverse events ( · HIV‐positive pregnant women co‐infected with hepatitis B virus
It is very uncertain whether tenofovir‐based antiviral combination regimens changes proportion of mothers with serious adverse events ( compared with placebo or tenofovir alone or non‐tenofovir‐based antiviral regimens (very low certainty).
1 finding from 1 review
Adverse events · adults with ALI
It is very uncertain whether ultrasound‐accelerated thrombolysis changes adverse events compared with thrombolysis alone (very low certainty).
1 finding from 1 review
Intervention not reported
Adverse events · people residing in communities endemic for onchocerciasis
The intervention probably leads to lower adverse events (moderate certainty).
1 finding from 1 review
no estimate extracted
2010 participants
Moderate
Adverse events within 28 days · people with SARS‐CoV‐2 infection and asymptomatic or mild disease
1 finding from 1 review
Serious adverse events
It is very uncertain whether single‐dose, preoperative MMC‐EMDA changes serious adverse events compared with TURBT alone (very low certainty).
1 finding from 1 review
Serious adverse events within 28 days · people with SARS‐CoV‐2 infection and asymptomatic or mild disease
1 finding from 1 review